Grifols, Brookfield Asset Management
Grifols Board Issues Unfavorable Opinion on Brookfield Offer
Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative offer, which values the Spanish drugmaker at €6.45 billion ($6.8 billion).Most Read from BloombergParis to Replace Parking Spaces With TreesNew York’s Transit Agency Approves $9 Congestion TollIn Cleveland,
Plasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer
With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...
Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 ...
Grifols (GRFS) stock gains as banks aim to finalize an €11B debt package for Brookfield's (BAM) plan to take the healthcare ...
Grifols said on Tuesday that Canadian investment fund Brookfield’s BN-T potential €6.45-billion ($6.8-billion) offer ...
(Bloomberg) -- Grifols SA’s board recommended that shareholders reject Brookfield Asset Management’s indicative offer, which values the Spanish drugmaker at €6.45 billion ($6.8 billion).
An investigating magistrate at Spain's High Court has opened a probe into U.S.-based short seller Gotham City Research's ...
GigaGen, a subsidiary of Grifols, has commenced a Phase I trial, with the first patient receiving a dose of GIGA-2339 aimed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback